ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Thymoglobulin Dose and Incidence of Biopsy Proven Acute Rejections in the Early Post Transplant Period

K. Shimko, K. Schonder, D. Jorgensen, K. Kalra, A. Cherukuri, R. Mehta, I. Melgarejo, P. Sood, S. Hariharan, R. Mehta

University of Pittsburgh Medical Center, Pittsburgh, PA

Meeting: 2020 American Transplant Congress

Abstract number: B-002

Keywords: Antilymphocyte antibodies, Biopsy, Kidney transplantation, Rejection

Session Information

Date: Saturday, May 30, 2020

Session Name: Poster Session B: Kidney Immunosuppression: Induction Therapy

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

Related Abstracts
  • Early Inflammatory Lesions on Surveillance Biopsies Post Kidney Transplant is Associated with Increased Incidence of Late Clinical Rejections
  • Thymoglobulin Dose and Effect on Short-Term Kidney Transplant Outcomes

*Purpose: Optimal dosing of thymoglobulin (ATG) for induction has not been well defined. Our protocol aims for 5-6mg/kg cumulative dose divided over 4 doses. However, it is unclear if lower dose ATG results in an increase in rejections (either subclinical or clinical TCMR or AMR) in the short term.

*Methods: Data collection was done through retrospective chart reviews of all patients who received a kidney transplant at our center between January 1, 2013 and December 31, 2017. Data collected included patient demographics, HLA mismatch, PRA, organ source, CIT, DSA, number and type of rejections, both subclinical and clinical, within the first 6 months post transplant. Patients who did not receive a biopsy within the first 6 months post transplant were excluded.

Table 1
Total (n=549) <5 (n=60) >=5 (n=489) P-value
Sex F M 222 (40.4%) 327 (59.6%) 16 (26.7%) 44 (73.3%) 206 (42.1%) 283 (57.9%) 0.021
PRA I>20 94 (17.2%) 5 (8.3%) 89 (18.3%) 0.05
PRA II>20 107 (19.6%) 2 (3.3%) 105 (21.6%) <0.001
TCMR (Banff 1A or greater) 145 (26.5%) 22 (37.3%) 123 (25.2%) 0.046

A total of 549 patients were divided into 2 groups; Grp 1 (n=60) those who received <5mg/kg ATG and Grp 2 (n=489) those who received >=5mg/kg. All rejections were biopsy proven and included both clinical and subclinical rejections. The Banff schema was followed for classification of rejections. Rejections were treated per center protocol.

*Results: Baseline characteristics were similar between groups except that Grp 2 had a greater proportion of patients with PRA>20. (Table 1). The vast majority of the rejections were T cell mediated (TCMR) and a small number were mixed. TCMR (Banff 1A or greater) was present in 37% of those who received <5mg/kg ATG vs 25% of those receiving >=5mg/kg (p=0.046). The odds of TCMR were 1.93(95% CI 1.08-3.5; p=0.027) times higher for those receiving <5mg/kg ATG compared with >=5mg/kg, independent of sex and PRA.

*Conclusions: Induction dose of ATG less than 5 mg/kg may be associated with a heightened risk of early rejections (subclinical or clinical) even in patients with low PRA.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Shimko K, Schonder K, Jorgensen D, Kalra K, Cherukuri A, Mehta R, Melgarejo I, Sood P, Hariharan S, Mehta R. Thymoglobulin Dose and Incidence of Biopsy Proven Acute Rejections in the Early Post Transplant Period [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/thymoglobulin-dose-and-incidence-of-biopsy-proven-acute-rejections-in-the-early-post-transplant-period/. Accessed January 23, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
    • Penis Transplantation: First U.S. Experience.
    • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
    • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
    • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
    • Home
    • Search
    • Penis Transplantation: First U.S. Experience.
    • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
    • Low GFR after Kidney Donation Is Not Chronic Kidney Disease

    Visit Our Partner Sites

    American Transplant Congress (ATC)

    Visit the official site for the American Transplant Congress »

    American Journal of Transplantation

    The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

    American Society of Transplantation (AST)

    An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

    American Society of Transplant Surgeons (ASTS)

    The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

    Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

    Privacy Policy

    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.
    This site uses cookies: Find out more.